(Q34792708)

4 August 2017

0 references

Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia (English)

1 reference

4 August 2017

1 reference

1 reference

2

Nakao Iwata

1 reference

4 August 2017

Taro Kishi

1

1 reference

4 August 2017

3 July 2013

1 reference

The International Journal of Neuropsychopharmacology

4 August 2017

1 reference

4 August 2017

17

1 reference

4 August 2017

343-354

1 reference

4 August 2017

2

1 reference

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

4 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Pharmacological properties of MO-8282, a novel antidepressant

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Positive vs. negative schizophrenia: a critical evaluation

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Negative symptoms in schizophrenia. Definition and reliability

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

A depression rating scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

CGS 7525A, A new, centrally active alpha2 adrenoceptor antagonist

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Investigation of clinical factors influencing cognitive function in Japanese schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Akathisia: an updated review focusing on second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Behavioral effects of a new antidepressant, setiptiline

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Negative symptoms in schizophrenia: avolition and Occam's razor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Mirtazapine: a review of its use in major depression and other psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Antipsychotic drugs and obesity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

How meta-analysis increases statistical power

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713000667

7 January 2021

10.1017/S1461145713000667

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

23823741